|
| 紫杉醇与多西他赛在ⅠB2期及ⅡA2期宫颈癌新辅助化疗中的疗效比较 |
| Clinical efficacy evaluation of paclitaxel or docetaxol in neoadjunvant chemotherapy for stage ⅠB2, ⅡA2 cervical cancer |
| 投稿时间：2016-05-10 |
| DOI：10.3969/j.issn.1000-0399.2016.11.003 |
| 中文关键词: 宫颈癌 紫杉醇 多西他赛 新辅助化疗 |
| 英文关键词: Cervical cancer Paclitaxel Docetaxol Neoadjuvant chemotherapy |
| 基金项目:国家自然科学基金（项目编号：81001168） |
|
| 摘要点击次数: 1618 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨紫杉醇与多西他赛在ⅠB2期及ⅡA2期宫颈癌新辅助化疗中的近期疗效及毒副反应。方法 回顾性分析安徽省立医院2014年1月至2016年1月122例宫颈癌患者临床资料，根据化疗方案的不同将患者分为两组：紫杉醇组（62例）采用紫杉醇联合奈达铂化疗；多西他赛组（60例）采用多西他赛联合奈达铂化疗。每3周为1个疗程，共2个疗程，3周后评估局部疗效，随即手术。结果 紫杉醇组和多西他赛组总有效率分别为59.68%（37/62）、53.33%（32/60），差异无统计学意义（P>0.05）。紫杉醇组引起过敏反应、神经毒性发生率高于多西他赛组，骨髓抑制发生率低于多西他赛组，差异均有统计学意义（P均<0.05），而在脱发、肌肉关节疼痛、恶性呕吐等毒副反应方面，两组差异无统计学意义（P>0.05）。紫杉醇组手术切除率为90.32%，多西他赛组手术切除率为95.00%，术后病理检查紫杉醇组淋巴转移9例（15.79%），多西他赛组淋巴转移11例（19.30%），差异均无统计学意义（P均>0.05）。结论 多西他赛联合奈达铂为局部晚期宫颈癌患者提供了有效、低毒副反应的新辅助化疗方案，可为患者赢得手术机会，其疗效与紫杉醇相似，但在过敏反应、神经毒性方面明显低于紫杉醇。 |
| 英文摘要: |
| Objective To compare the short-term clinical efficacy and safety of docetaxol with paclitaxel in neoadjunvant chemotherapy for the patients with stage ⅠB2, ⅡA2 cervical cancer.Methods The clinical data of 122 patients with stage ⅠB2, ⅡA2 cervical cancer ever treated in our hospital from Jan 2014 to Jan 2016 were retrospectively analyzed.Based on the dosing regimens, all cases were divided into the paclitaxel group (n=62) and the docetaxol group (n=60).The patients in the paclitaxel group were treated with paclitaxel and nedaplatin, and the docetaxol group was given docetaxol and nedaplatin, with 3 weeks as a cycle for 2 cycles.Those patients underwent evaluation of the local therapeutic effects and toxicity at the end of the second treatment cycle, and then were operated.Results The total effective rate in the paclitaxel group and the docetaxol group were 59.68% and 53.33%, respectively, and their difference was not statistically significant (P>0.05).No significant difference was found between the two groups when referring to such adverse effects as hair loss, pain in the muscles and joints, nausea and vomiting, etc (P>0.05).In comparison with the docetaxol group, patients in the paclitaxel group had significantly higher incidences of allergic reaction and peripheral neuritis, and much lower occurrence rate of arrest of bone marrow (all P<0.05).56 (90.32%) patients in the paclitaxel group underwent tumor resection and 9 (15.79%) cases were pathologically diagnosed with lymphatic metastasis, while 57 (95.00%) patients in the docetaxol group underwent the same surgery and 11 (19.30%) cases with lymphatic metastasis.There was no significant difference in the resection and metastasis rates between the two groups (all P>0.05).Conclusion Docetaxol combined with nedaplatin would be an effective and low-toxic treatment regimen of neoadjunvant chemotherapy for those patients with locally advanced cervical cancer, with similar clinical efficacy to the regimen of paclitaxel combined with nedaplatin and unusually less adverse reactions of allergic reaction and peripheral neuritis, so that it might provide more chance to receive operation and better prognosis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
